Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging.

In this study, we demonstrate a method to quantify biomarker expression that uses an exogenous dual-reporter imaging approach to improve tumor signal detection. The uptake of two fluorophores, one nonspecific and one targeted to the epidermal growth factor receptor (EGFR), were imaged at 1 h in three types of xenograft tumors spanning a range of EGFR expression levels (n=6 in each group). Using this dual-reporter imaging methodology, tumor contrast-to-noise ratio was amplified by >6 times at 1 h postinjection and >2 times at 24 h. Furthermore, by as early as 20 min postinjection, the dual-reporter imaging signal in the tumor correlated significantly with a validated marker of receptor density (P<0.05, r=0.93). Dual-reporter imaging can improve sensitivity and specificity over conventional fluorescence imaging in applications such as fluorescence-guided surgery and directly approximates the receptor status of the tumor, a measure that could be used to inform choices of biological therapies.

[1]  V. Chernomordik,et al.  Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. , 2009, Molecular imaging.

[2]  R. Weissleder,et al.  In vivo imaging of tumors with protease-activated near-infrared fluorescent probes , 1999, Nature Biotechnology.

[3]  J F Gross,et al.  Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. , 1989, International journal of radiation oncology, biology, physics.

[4]  Yasuyoshi Watanabe,et al.  [Molecular imaging for drug development]. , 2007, Brain and nerve = Shinkei kenkyu no shinpo.

[5]  D. M. Olive,et al.  A systematic approach to the development of fluorescent contrast agents for optical imaging of mouse cancer models. , 2007, Analytical biochemistry.

[6]  P. Low,et al.  Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results , 2011, Nature Medicine.

[7]  M. Korc,et al.  Binding of epidermal growth factor in rat pancreatic acini. , 1983, Biochemical and biophysical research communications.

[8]  G. Lappin.  Microdosing: current and the future. , 2010, Bioanalysis.

[9]  Brian W Pogue,et al.  Review of Neurosurgical Fluorescence Imaging Methodologies , 2010, IEEE Journal of Selected Topics in Quantum Electronics.

[10]  E. Kim,et al.  Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. , 1980, Cancer research.

[11]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[12]  Tayyaba Hasan,et al.  Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy of murine gliomas. , 2010, Academic radiology.

[13]  D. Bigner,et al.  EGF mutant receptor vIII as a molecular target in cancer therapy. , 2001, Endocrine-related cancer.

[14]  R K Jain,et al.  Transport of molecules, particles, and cells in solid tumors. , 1999, Annual review of biomedical engineering.

[15]  P. Choyke,et al.  Near infrared fluorescence‐guided real‐time endoscopic detection of peritoneal ovarian cancer nodules using intravenously injected indocyanine green , 2011, International journal of cancer.

[16]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  J. Frangioni,et al.  Image-Guided Surgery Using Invisible Near-Infrared Light: Fundamentals of Clinical Translation , 2010, Molecular imaging.

[18]  Walter J. Riker.  A Review of J , 2010 .

[19]  R. Jain,et al.  Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. , 1996, Microvascular research.

[20]  L. Ngo,et al.  The FLARE™ Intraoperative Near-Infrared Fluorescence Imaging System: A First-in-Human Clinical Trial in Breast Cancer Sentinel Lymph Node Mapping , 2009, Annals of Surgical Oncology.

[21]  Jason R. Gunn,et al.  In Vivo Quantification of Tumor Receptor Binding Potential with Dual-Reporter Molecular Imaging , 2012, Molecular Imaging and Biology.

[22]  A. Bradwell,et al.  Radioimmunodetection of gastrointestinal neoplasms with antibodies to carcinoembryonic antigen. , 1980, Cancer research.

[23]  Vladimir Tolmachev,et al.  Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Christopher H Contag,et al.  Quantifying cell-surface biomarker expression in thick tissues with ratiometric three-dimensional microscopy. , 2009, Biophysical journal.

[25]  Tayyaba Hasan,et al.  Imaging targeted-agent binding in vivo with two probes. , 2010, Journal of biomedical optics.

[26]  P. Merlet,et al.  In vivo quantification and parametric images of the cardiac beta-adrenergic receptor density. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[28]  V. Chernomordik,et al.  In Vivo Method to Monitor Changes in HER2 Expression Using Near-Infrared Fluorescence Imaging , 2012, Molecular imaging.

[29]  Aya Nakagawa,et al.  Intraoperative identification of sentinel lymph nodes by near-infrared fluorescence imaging in patients with breast cancer. , 2008, American journal of surgery.

[30]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[31]  Xiaoyao Fan,et al.  Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between δ-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. , 2011, Journal of neurosurgery.

[32]  V. Chernomordik,et al.  Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging , 2008, Clinical Cancer Research.

[33]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  M. Korc,et al.  Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Anna M Wu,et al.  Antibody vectors for imaging. , 2010, Seminars in nuclear medicine.

[36]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[37]  R. Weissleder,et al.  Fluorescence molecular tomography resolves protease activity in vivo , 2002, Nature Medicine.

[38]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[39]  Brian W. Pogue,et al.  High Vascular Delivery of EGF, but Low Receptor Binding Rate Is Observed in AsPC-1 Tumors as Compared to Normal Pancreas , 2011, Molecular Imaging and Biology.

[40]  R. Weissleder,et al.  Imaging in the era of molecular oncology , 2008, Nature.

[41]  R. McLendon,et al.  Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.

[42]  Milton V. Marshall,et al.  Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study. , 2008, Radiology.